drugset / Trial / NCT01716026

Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia

NCT01716026 ↗

Phase 3 Completed 66 enrolled Institute of Applied Ophthalmobiology - IOBA
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this protocol is to determine wether the initial protocol in the treatment of subfoveal choroidal neovascularization associated to High Myopia with bevacizumab intravitreal injections is more effective when using 3 doses vs using 1 single dose in the load period

Timeline

Start
2012-10
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — Intravitreal